Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study

Physiological Genomics

Volumn 48, Issue 1, 2016, Pages 33-41

  Miller, Virginia M ^a,b   Jenkins, Gregory D ^a   Biernacka, Joanna M ^a   Heit, John A ^a   Huggins, Gordon S ^c   Hodis, Howard N ^d   Budoff, Matthew J ^e   Lobo, Rogerio A ^f   Taylor, Hugh S ^g   Manson, Joann E ^h   Black, Dennis M ⁱ   Naftolin, Frederick ^j   Mitchell Harman, S ^k   de Andrade, Mariza ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^f Yale University School of Medicine ^*  (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k CARL T HAYDEN VA MEDICAL CENTER   (United States)

more..

Author keywords

Atherosclerosis; Candidate genes; Estrogen; Innate immunity; Thrombosis

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; PLACEBO; PROGESTERONE;

ARTERIAL WALL THICKNESS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HORMONAL THERAPY; HUMAN; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; ANIMAL; CALCINOSIS; CAROTID ARTERY; CONFIDENCE INTERVAL; CORONARY BLOOD VESSEL; DRUG EFFECTS; GENETIC ASSOCIATION STUDY; GENETICS; HORSE; PATHOLOGY; PHARMACOGENETICS; TIME FACTOR;

ANIMALS; CALCINOSIS; CAROTID ARTERIES; CAROTID INTIMA-MEDIA THICKNESS; CONFIDENCE INTERVALS; CORONARY VESSELS; ESTROGENS; FEMALE; GENETIC ASSOCIATION STUDIES; HORSES; HUMANS; IMMUNITY, INNATE; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; TIME FACTORS;

EID: 84953293848     PISSN: 10948341     EISSN: 15312267     Source Type: Journal    
DOI: 10.1152/physiolgenomics.00029.2015     Document Type: Article

References (38)

1. Alessio AM, Hoehr NF, Siqueira LH, Ozelo MC, de Padua Mansur A, Annichino-Bizzacchi JM. Association between estrogen receptor alpha and beta gene polymorphisms and deep vein thrombosis. Thromb Res 120: 639-645, 2007.
2. Bairey Merz CN, Mark S, Boyan BD, Jacobs AK, Shah PK, Shaw LJ, Taylor D, Marban E. Proceedings from the scientific symposium: sex differences in cardiovascular disease and implications for therapies. J Womens Health (Larchmt) 19: 1059-1072, 2010.
3. Biernacka JM, Jenkins GD, Wang L, Moyer AM, Fridley BL. Use of the gamma method for self-contained gene-set analysis of SNP data. Eur J Hum Genet 20: 565-571, 2012.
4. Bray PF, Larson JC, Lacroix AZ, Manson J, Limacher MC, Rossouw JE, Lasser NL, Lawson WE, Stefanick ML, Langer RD, Margolis KL. Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. Am J Cardiol 101: 1599-1605, 2008.
5. Burdon KP, Langefeld CD, Beck SR, Wagenknecht LE, Carr JJ, Rich SS, Freedman BI, Herrington D, Bowden DW. Variants of the CD40 gene but not of the CD40L gene are associated with coronary artery calcification in the Diabetes Heart Study (DHS). Am Heart J 151: 706- 711, 2006.
6. Bush TL, Barrett-Connor E. Noncontraceptive estrogen use and cardiovascular disease. Epidemiol Rev 7: 89-104, 1985.
7. Buzkova P, Lumley T, Rice K. Permutation and parametric bootstrap tests for gene-gene and gene-environment interactions. Ann Hum Genet 75: 36-45, 2011.
8. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PV. Hormone therapy and venous thromboembolism among postmenopausal women. Circulation 115: 840-845, 2007.
9. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115: 840-845, 2007.
10. Cecelja M, Jiang B, Bevan L, Frost ML, Spector TD, Chowienczyk PJ. Arterial stiffening relates to arterial calcification but not to noncalcified atheroma in women. A twin study. J Am Coll Cardiol 57: 1480-1486, 2011.
11. Gao X, Starmer J, Martin ER. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genet Epidemiol 32: 361-369, 2008.
12. Glueck CJ, Ping W, Fontaine RN, Trent T, Sieve-Smith L, Lang JE. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the Factor V Leiden mutation (resistance to activated protein C). Am J Cardiol 84: 549-554, 1999.
13. Goeman JJ, van de Geer SA, de Kort F, van Houwelingen HC. A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 20: 93-99, 2004.
14. Harman SM, Black DM, Naftolin F, Brinton EA, Budoff MJ, Cedars MI, Hopkins PN, Lobo RA, Manson JEM, GR, Miller VM, Neal-Perry G, Santoro N, Taylor HS, Vittinghoff E, Yan M, Hodis HN. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: A randomized trial. Ann Intern Med 161: 249-260, 2014.
15. Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, Miller VM, Naftolin F, Santoro N. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 8: 3-12, 2005.
16. Harman SM, Vittinghoff E, Brinton EA, Budoff MJ, Cedars MI, Lobo RA, Merriam GR, Miller VM, Naftolin F, Pal L, Santoro N, Taylor HS, Black DM. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am J Med 124: 199-205, 2011.
17. Heit JA, Cunningham JM, Petterson TM, Armasu SM, Rider DN, De Andrade M. Genetic variation within the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways as risk factors for venous thromboembolism. J Thromb Haemost 9: 113-1142, 2011.
18. Hodis H, Mack W, Lobo R, Shoupe D, Sevanian A, Mahrer P, Selzer R, Liu C, Liu C, Azen S. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 135: 939-953, 2001.
19. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, Azen SP. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 128: 262-269, 1998.
20. Joyner MJ, Barnes JN, Hart EC, Wallin BG, Charkoudian N. Neural control of the circulation: how sex and age differences interact in humans. Compr Physiol 5: 193-215, 2015.
21. Juo SH. Genetics of carotid atherosclerosis. Front Biosci 14: 4525-4534, 2009.
22. Karim R, Hodis HN, Stanczyk FZ, Lobo RA, Mack WJ. Relationship between serum levels of sex hormones and progression of subclinical atherosclerosis in postmenopausal women. J Clin Endocrinol Metab 93: 131-138, 2008.
23. Kunnas TA, Laippala P, Penttilä A, Lehtimäki T, Karhunen PJ. Association of polymorphism of human alpha oestrogen receptor gene with coronary artery disease in men: a necropsy study. BMJ 321: 273-274, 2000.
24. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349: 523-534, 2003.
25. Miller VM, Black DM, Brinton EA, Budoff MJ, Cedars MI, Hodis HN, Lobo RA, Manson JE, Merriam GR, Naftolin F, Santoro N, Taylor HS, Harman SM. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res 2: 228-239, 2009.
26. Miller VM, Petterson TM, Jeavons EN, Lnu AS, Rider DN, Heit JA, Cunningham JM, Huggins GS, Hodis HN, Budoff MJ, Santoro N, Hopkins PN, Lobo RA, Manson JE, Naftolin F, Taylor HS, Harman SM, de Andrade M. Genetic polymorphisms associated carotid artery intimamedia thickness and coronary artery calcification in women of the Kronos Early Estrogen Prevention Study. Physiol Genomics 45: 79-88, 2013.
27. Moreau KL, Donato AJ, Seals DR, DeSouza CA, Tanaka H. Regular exercise, hormone replacement therapy and the age-related decline in carotid arterial compliance in healthy women. Cardiovasc Res 57: 861- 868, 2003.
28. O'Donnell CJ, Cupples LA, D'Agostino RB, Fox CS, Hoffmann U, Hwang SJ, Ingellson E, Liu C, Murabito JM, Polak JF, Wolf PA, Demissie S. Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's Framingham Heart Study. BMC Med Genet 8, Suppl 1: S4, 2007.
29. Payami H, Zareparsi S, Montee KR, Sexton GJ, Kaye JA, Bird TD, Yu CE, Wijsman EM, Heston LL, Litt M, Schellenberg GD. Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. Am J Hum Genet 58: 803-811, 1996.
30. Rexrode KM, Manson JE, Lee IM, Ridker PM, Sluss PM, Cook NR, Buring JE. Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation 108: 1688-1693, 2003.
31. Rossouw J, Bray P, Liu J, Kooperberg C, Hsia J, Lewis C, Cushman M, Bonds D, Hendrix S, Papanicolaou G, Howard T, Herrington D. Estrogen receptor polymorphisms and the vascular effects of hormone therapy. Arterioscler Thromb Vac Biol 31: 464-469, 2011.
32. Seldin MF, Shigeta R, Villoslada P, Selmi C, Tuomilehto J, Silva G, Belmont JW, Klareskog L, Gregersen PK. European population substructure: clustering of northern and southern populations. PLoS Genet 2: e143, 2006.
33. Shufelt CL, Merz CN, Prentice RL, Pettinger MB, Rossouw JE, Aroda VR, Kaunitz AM, Lakshminarayan K, Martin LW, Phillips LS, Manson JE. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study. Menopause 21: 260-266, 2013.
34. Sudhir K, Chou TM, Chatterjee K, Smith EP, Williams TC, Kane JP, Malloy MJ, Korach KS, Rubanyi GM. Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation 96: 3774-3777, 1997.
35. Tempfer CB, Riener EK, Hefler LA, Huber JC, Muendlein A. DNA microarray-based analysis of single nucleotide polymorphisms may be useful for assessing the risks and benefits of hormone therapy. Fertil Steril 82: 132-137, 2004.
36. Waddell TK, Rajkumar C, Cameron JD, Jennings GL, Dart AM, Kingwell BA. Withdrawal of hormonal therapy for 4 weeks decreases arterial compliance in postmenopausal women. J Hypertens 17: 413-418, 1999.
37. Wang L, Beecham A, Zhuo D, Dong C, Blanton SH, Rundek T, Sacco RL. Fine mapping study reveals novel candidate genes for carotid intimamedia thickness in Dominican Republican families. Circ Cardiovasc Genet 5: 234-241, 2012.
38. Wharton W, Gleason CE, Dowling NM, Carlsson CM, Brinton EA, Santoro MN, Neal-Perry G, Taylor H, Naftolin F, Lobo RA, Merriam G, Manson JE, Cedars MI, Miller VM, Black DM, Budoff M, Hodis HN, Harman SM, Asthana S. The KEEPS-Cognitive and Affective Study: baseline associations between vascular risk factors and cognition. J Alzheimers Dis 40: 331-341, 2014.